Clinical Trial

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2020-07-15; most recent amendment 2026-02-05.
Status change: Recruiting → Active, Not Recruiting 2024-08-08
Trial Details
NCT Number NCT04478279
Lead Sponsor Sapience Therapeutics
Conditions Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer +6 more
Enrollment 125 participants
Start Date 2020-07-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-09